SpeeDx Begins Multisite U.S. Clinical Trials of ResistancePlus® MG Test
September 25, 2018 08:00 ET | SpeeDx Pty Ltd
SYDNEY, Australia, Sept. 25, 2018 (GLOBE NEWSWIRE) -- SpeeDx Pty. Ltd. today announced the start of patient testing in their multisite U.S.-based clinical trials for ResistancePlus® MG (not...
UK drafts new M. genitalium guidelines: Resistance Guided Therapy to tackle antibiotic resistance
July 23, 2018 03:00 ET | SpeeDx Pty Ltd
LONDON, July 23, 2018 (GLOBE NEWSWIRE) -- The British Association of Sexual Health and HIV (BASHH) draft guidelines for the sexually transmitted infection Mycoplasma genitalium (Mgen) were posted...
SpeeDx Pty. Ltd. establishes US-based operation
December 04, 2017 08:00 ET | SpeeDx Pty Ltd
SYDNEY, Australia, Dec. 04, 2017 (GLOBE NEWSWIRE) -- SpeeDx Pty. Ltd, a developer of advanced multiplex molecular diagnostic solutions, announced the incorporation of a US-based subsidiary company,...